Title:
USE OF COMBINATION OF COMPOUND OF SCLEROTIORIN AND RIFAMPICIN IN PREPARATION OF ANTI-TUBERCULOSIS DRUG
Document Type and Number:
WIPO Patent Application WO/2021/000062
Kind Code:
A1
Abstract:
Disclosed is the use of a combination of a compound of sclerotiorin and rifampicin in the preparation of an anti-tuberculosis drug. In the present invention, a Mycobacterium tuberculosis (Mtb) H37Rv(Rv) aerosol is used to infect a BALB/c mouse model, and the in vivo activity of the compound of sclerotiorin (SLT) used alone and in combination with rifampicin (RIF) against Mycobacterium tuberculosis is studied. As a result, compared with the untreated group and prior to treatment, when the administration dosage is 100 mg/kg and 300 mg/kg, SLT has an obvious bactericidal effect on Mycobacterium tuberculosis in vivo; and when used in combination with RIF, SLT has an enhanced bactericidal effect in vivo and displays a very obvious synergy, and SLT is dose-dependent.
Inventors:
LU YONGJUN (CN)
CHEN DONGNI (CN)
SHE ZHIGANG (CN)
SHEN DONG (CN)
WANG QINGLIN (CN)
HE LEI (CN)
YUAN PEIBO (CN)
CHEN DONGNI (CN)
SHE ZHIGANG (CN)
SHEN DONG (CN)
WANG QINGLIN (CN)
HE LEI (CN)
YUAN PEIBO (CN)
Application Number:
PCT/CN2019/093937
Publication Date:
January 07, 2021
Filing Date:
June 29, 2019
Export Citation:
Assignee:
UNIV SUN YAT SEN (CN)
International Classes:
A61K31/496; A61K31/4409; A61P31/06
Foreign References:
| CN106420755A | 2017-02-22 | |||
| CN108658924A | 2018-10-16 | |||
| US20130197071A1 | 2013-08-01 |
Attorney, Agent or Firm:
YOGO PATENT & TRADEMARK AGENCY LIMITED COMPANY (CN)
Download PDF: